Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Could Lipids Be a Key to Control Inflammation?

Gretchen Henkel  |  Issue: March 2011  |  March 18, 2011

Animals were divided into four groups. Rats in the control group were given IV saline injections at the acute and chronic phases. The other three groups of animals received IV injections of apoA-1 (the main apolipoprotein in HDL) either alone or in combination with saline at different time periods: a single treatment during either the acute or chronic phases of inflammation, or, as in group 4, injections of only apoA-1 during both the acute and chronic phases. Regardless of when the apoA-1 was administered, the injection produced a markedly reduced inflammatory response. The team also looked at T-cell and monocyte activation in all groups of animals. They found that, irrespective of the timing of the apoA-1 injection, the T-cell and monocyte counts were reduced nearly to baseline levels by the end of the experimental period (21 days from injection of PG-PS).

From these preliminary results, the team concluded that apoA-1 inhibits PG-PS–induced T-cell activation and cytokine production, and that it is effective in inhibiting joint inflammation in the Lewis rat. This study is part of an ongoing project, Dr. Rye noted, and her team has retained plasma and tissue samples from the animals to further test the levels of a list of chemokines to see whether the results hold. “We’re going to be looking much more closely at these markers and see if we can identify some of the pathways that are involved in mediating these effects,” she said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Linking Cholesterol Transport and Inflammation

Uwe J. F. Tietge, MD, PhD, professor of pediatrics at the Center for Liver, Digestive, and Metabolic Diseases at the University Medical Center Groningen, The Netherlands, also spoke at the session. In his talk entitled, “Liver X Receptor Signaling at the Crossroads between Immunity and Cholesterol Homeostasis,” Dr. Tietge first summarized the large body of work on reverse cholesterol transport (RCT), a process mediated by LXR transcription. Liver X receptors (LXRs) function as nuclear cholesterol sensors that are activated in response to elevated intracellular cholesterol levels in multiple cell types.2 When LXRs are activated, they induce expression of an array of genes involved in cholesterol absorption, efflux, transport, and excretion. “Globally,” noted Dr. Tietge, “LXR activation coordinates the response to eliminate cholesterol from the body.” LXRα, the alpha isoform, is mainly expressed in the liver, intestine, kidney, adrenals, adipose tissue, and macrophages. The beta isoform of LXR (LXRβ) is more ubiquitously expressed.

LXR activation also increases the expression of antiinflammatory genes. The ability of LXRs to integrate metabolic and inflammatory signaling makes them potentially attractive targets for designing interventions in metabolic disease.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsRheumatoid Arthritis Tagged with:Cardiovascular diseasecholesterolhigh-density lipoproteininflammationLipidRheumatoid arthritis

Related Articles

    Researchers Work to Untangle the Relationship Between Blood Lipids, Bone Health & Diet

    May 2, 2016

    A recent editorial examined research findings on how low levels of high-density lipoprotein (HDL) in the blood affect bone health, resulting in cartilage dysfunction and the development of osteoarthritis (OA). Authors note that a high-fat diet in mice with HDL deficiency resulted in OA development; thus, they conclude that in patients with metabolic syndrome, HDL may have a causative relationship to OA…

    Cholesterol Levels in Patients with RA Starting Methotrexate

    February 25, 2016

    Although research regarding the increased cardiovascular (CV) morbidity and mortality in rheumatoid arthritis (RA) has burgeoned in recent years, the need remains for a better understanding of the effects of widely used DMARDs on CV risk and risk factors in RA patients. These authors set out to evaluate the long-term changes in cholesterol levels in patients with early RA. Decreases in RA disease activity over long-term follow-up were associated with increases in cholesterol levels in patients with early RA treated with either biologic or nonbiologic therapies…

    Cardiovascular Disease Risk High in RA Patients

    June 1, 2010

    High incidence of metabolic disease and concurrent inflammation increases risk

    Patients with RA Who Respond to Treatment Experience Increased Cholesterol

    June 6, 2016

    New research confirms that patients with rheumatoid arthritis who respond to treatment experience an increase in cholesterol levels, including total cholesterol, LDL-C and HDL-C levels. However, the use of triple therapy may be important for understanding this association and mitigating its risk…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences